Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Not Recruiting

Open to: ALL

Age: 10.0 - N/A

Medical Conditions

Liposarcoma
Sarcoma, Synovial
Liposarcoma, Myxoid


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2019 Oct 2022

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Letetresgene autoleucel will be administered.

Intervention Arm Group : Letetresgene autoleucel;

Intervention Type : DRUG
Intervention Description : Cyclophosphamide will be used as a lymphodepleting chemotherapy.

Intervention Arm Group : Letetresgene autoleucel;

Intervention Type : DRUG
Intervention Description : Fludarabine will be used as a lymphodepleting chemotherapy.

Intervention Arm Group : Letetresgene autoleucel;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • GSK Investigational Site
    London
    SW3 6JJ


The study is sponsored by GlaxoSmithKline




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT05993299
Last updated 18 September 2023

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.